Fintel reports that on December 4, 2025, Scotiabank maintained coverage of Bristol-Myers Squibb (NYSE:BMY) with a Sector ...
Bristol-Myers Squibb shares gained after the company announced that it will enroll additional patients in the ADEPT-2 study.
The Prudent Speculator is an investment newsletter that has been published monthly since 1977. Buckingham and his team run four value-stock portfolios. The flagship Prudent Speculator Portfolio has ...
Pre-tax profits at the main Irish unit of pharma giant, Bristol Myers Squibb last year declined by 47% to $2.09 billion ...
Pfizer(NYSE: PFE) and Bristol Myers Squibb(NYSE: BMY) are two of the largest and most respected pharmaceutical companies in ...
Bayer reported positive Phase 3 results for its FXIa inhibitor asundexian, hitting key efficacy and safety targets ...
The Schwab U.S. Dividend Equity ETF currently trades at about $27 per share. So, your $500 will buy you about 18 shares. The ...
Bristol Myers Squibb has struggled over the past few years due to patent cliffs. And to make matters worse, it will soon face ...
One particularly appealing dividend stock right now is Bristol Myers Squibb ( BMY 0.10%). It yields 5.4%, which is an ...
Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 3 stocks made the list for top value stocks in the Pharmaceuticals ...
Bristol Myers Squibb BMY and Gilead Sciences, Inc. GILD are leading biotechnology companies with broad, diverse portfolios ...
Bristol-Myers Squibb Company, Newtek Business Services Corp, Sonoco Products Company. Read 's Market Analysis on Investing.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback